Nizar Y Saad[Author] - Search Results

Year	Number of Results
2012	1
2013	1
2015	1
2017	1
2018	2
2021	1
2022	1
2023	1
2024	0

1

Post-Translational Modifications of the DUX4 Protein Impact Toxic Function in FSHD Cell Models.

Knox RN, Eidahl JO, Wallace LM, Choudury SG, Rashnonejad A, Daman K, Guggenbiller MJ, Saad NY, Hoover ME, Zhang L, Branson OE, Emerson CP Jr, Freitas MA, Harper SQ. Knox RN, et al. Among authors: saad ny. Ann Neurol. 2023 Aug;94(2):398-413. doi: 10.1002/ana.26668. Epub 2023 May 19. Ann Neurol. 2023. PMID: 37186119

2

The DUX4 protein is a co-repressor of the progesterone and glucocorticoid nuclear receptors.

Quintero J, Saad NY, Pagnoni SM, Jacquelin DK, Gatica LV, Harper SQ, Rosa AL. Quintero J, et al. Among authors: saad ny. FEBS Lett. 2022 Oct;596(20):2644-2658. doi: 10.1002/1873-3468.14416. Epub 2022 Jun 15. FEBS Lett. 2022. PMID: 35662006 Free article.

3

Two-codon T-box riboswitch binding two tRNAs.

Saad NY, Stamatopoulou V, Brayé M, Drainas D, Stathopoulos C, Becker HD. Saad NY, et al. Proc Natl Acad Sci U S A. 2013 Jul 30;110(31):12756-61. doi: 10.1073/pnas.1304307110. Epub 2013 Jul 15. Proc Natl Acad Sci U S A. 2013. PMID: 23858450 Free PMC article.

4

Human miRNA miR-675 inhibits DUX4 expression and may be exploited as a potential treatment for Facioscapulohumeral muscular dystrophy.

Saad NY, Al-Kharsan M, Garwick-Coppens SE, Chermahini GA, Harper MA, Palo A, Boudreau RL, Harper SQ. Saad NY, et al. Nat Commun. 2021 Dec 8;12(1):7128. doi: 10.1038/s41467-021-27430-1. Nat Commun. 2021. PMID: 34880230 Free PMC article.

5

AAV-mediated follistatin gene therapy improves functional outcomes in the TIC-DUX4 mouse model of FSHD.

Giesige CR, Wallace LM, Heller KN, Eidahl JO, Saad NY, Fowler AM, Pyne NK, Al-Kharsan M, Rashnonejad A, Chermahini GA, Domire JS, Mukweyi D, Garwick-Coppens SE, Guckes SM, McLaughlin KJ, Meyer K, Rodino-Klapac LR, Harper SQ. Giesige CR, et al. Among authors: saad ny. JCI Insight. 2018 Nov 15;3(22):e123538. doi: 10.1172/jci.insight.123538. JCI Insight. 2018. PMID: 30429376 Free PMC article.

6

Pre-clinical Safety and Off-Target Studies to Support Translation of AAV-Mediated RNAi Therapy for FSHD.

Wallace LM, Saad NY, Pyne NK, Fowler AM, Eidahl JO, Domire JS, Griffin DA, Herman AC, Sahenk Z, Rodino-Klapac LR, Harper SQ. Wallace LM, et al. Among authors: saad ny. Mol Ther Methods Clin Dev. 2017 Dec 24;8:121-130. doi: 10.1016/j.omtm.2017.12.005. eCollection 2018 Mar 16. Mol Ther Methods Clin Dev. 2017. PMID: 29387734 Free PMC article.

7

A glyS T-box riboswitch with species-specific structural features responding to both proteinogenic and nonproteinogenic tRNAGly isoacceptors.

Apostolidi M, Saad NY, Drainas D, Pournaras S, Becker HD, Stathopoulos C. Apostolidi M, et al. Among authors: saad ny. RNA. 2015 Oct;21(10):1790-806. doi: 10.1261/rna.052712.115. Epub 2015 Aug 14. RNA. 2015. PMID: 26276802 Free PMC article.

8

Riboswitch (T-box)-mediated control of tRNA-dependent amidation in Clostridium acetobutylicum rationalizes gene and pathway redundancy for asparagine and asparaginyl-trnaasn synthesis.

Saad NY, Schiel B, Brayé M, Heap JT, Minton NP, Dürre P, Becker HD. Saad NY, et al. J Biol Chem. 2012 Jun 8;287(24):20382-94. doi: 10.1074/jbc.M111.332304. Epub 2012 Apr 13. J Biol Chem. 2012. PMID: 22505715 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

8 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year